Details of the financing agreement signed by MedinCell and the European Investment Bank (EIB)

November 23, 2022

MedinCell and EIB today announced the execution of the new credit facility of 40 million euros following the previous communication of Sept. 5th 

Under the agreement, MedinCell will repay immediately to EIB a previous 20 million euros loan and associated capitalized interest 

Extension of cash visibility (excluding potential additional revenue from partners): 

• 30 million euros of the credit facility drawable in Q4 2022 
Disbursement of remaining 10 million euros that is conditioned to approval by U.S. FDA of the first product based on MedinCell technology expected in H1 2023, will extend cash visibility until at least Q1 2024 

Each tranche of the new credit facility will be reimbursed 5 years after drawdown 

Session en français

Rendez-vous le lundi 14 novembre à 18h00 (CET) pour une vidéoconférence dédiée aux récentes avancées des produits de notre portfeuille clinique

English session

On Monday 14, November at 6.00 pm (CET) participate in our videoconference dedicated to the latest news regarding our clinical and regulatory products

Êtes-vous un actionnaire de MedinCell ? / Are you a MedinCell shareholder?
Vous êtes / You are :
This field is for validation purposes and should be left unchanged.


  • This field is for validation purposes and should be left unchanged.